



Financial Results for the 2nd Quarter of the Year Ending March 31, 2026

November 6, 2025

1. Report on Management Status

2. Financial Results for the 2nd Quarter of the Year Ending March 31, 2026

3. Forecast for the Year Ending March 31, 2026

Progress Made This Fiscal Year



Quality of life	Imaging Products	Launched our first digital cinema camera “ZR” , which incorporates RED technology Expanded our lineup of interchangeable lenses for mirrorless cameras to a cumulative 50 lenses
	Healthcare	Rolled out global marketing initiatives celebrating microscope business centennial, and promoted drug discovery support Nikon CeLL innovation’s Contract Cell Development and Manufacturing approved for METI subsidies ^{*1}
Industry	Precision Equipment	Began orders for “DSP-100” a digital lithography system for semiconductor back-end processes and advanced packaging Strengthened SCREEN ^{*2} partnership in wafer bonding technology for growing semiconductor back-end process market Made steady progress in development of next-generation ArF immersion lithography system for front-end processes
	Components	Resolved to dissolve Nikon Metrology NV as part of restructuring in the formerly Industrial Metrology (tax benefits) Developing new EUV related components in preparation for future diversification of demand
	Digital Manufacturing	Developing core tech for metal 3D additive manufacturing for large-scale precision parts under JAXA Space Strategy Fund Nikon SLM Solutions developing new models for further growth, mainly in defense and space segments Also driving profitability measures
Business Fundamentals		Pursuing balance sheet efficiency and consolidation/reorganization of footprint in Japan and abroad, including the sale of our Yokohama Plant
Changes in Major Shareholders ^{*3}		EssilorLuxottica owns 10.75% (as of Oct 1 st). Obtained clearance to own up to 20%

Our next Medium-Term Management Plan (Apr 2026 to Mar 2031) aims to balance recovering short-term business performance with investing for long-term growth

^{*1} Subsidy for Investment in Manufacturing Facilities for Regenerative, Cellular, and Gene Therapy ^{*2} Refer to our press release dated Oct 31.

^{*3} Refer to timely disclosure dated Oct 6 (Notice of Change in Major Shareholder and Largest Shareholder)